Back to Search
Start Over
Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy.
- Source :
-
Frontiers in immunology [Front Immunol] 2018 Jul 27; Vol. 9, pp. 1739. Date of Electronic Publication: 2018 Jul 27 (Print Publication: 2018). - Publication Year :
- 2018
-
Abstract
- Immune checkpoint inhibitors (ICIs) have recently revolutionized cancer treatment, providing unprecedented clinical benefits. However, primary or acquired therapy resistance can affect up to two-thirds of patients receiving ICIs, underscoring the urgency to elucidate the mechanisms of treatment resistance and to design more effective therapeutic strategies. Conventional cancer treatments, including cytotoxic chemotherapy, radiation therapy, and targeted therapy, have immunomodulatory effects in addition to direct cancer cell-killing activities. Their clinical utilities in combination with ICIs have been explored, aiming to achieve synergetic effects with improved and durable clinical response. Here, we will review the immunomodulatory effects of chemotherapy, targeted therapy, and radiation therapy, in the setting of ICI, and their clinical implications in reshaping modern cancer immunotherapy.
- Subjects :
- Animals
Antineoplastic Agents, Immunological administration & dosage
Antineoplastic Combined Chemotherapy Protocols adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Biomarkers, Tumor
Clinical Trials as Topic
Humans
Immunomodulation drug effects
Immunotherapy
Molecular Targeted Therapy
Neoplasms etiology
Neoplasms mortality
Neoplasms pathology
Radiotherapy methods
Treatment Outcome
Antineoplastic Agents, Immunological therapeutic use
Combined Modality Therapy
Neoplasms therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 9
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 30100909
- Full Text :
- https://doi.org/10.3389/fimmu.2018.01739